Perrigo (PRGO) recently moved within the Russell index family, exiting several Russell 1000 and Midcap indices and joining the Russell 2000. This is a technical reshuffle that can influence short term trading flows.
See our latest analysis for Perrigo.
These index moves come after a weak period for Perrigo’s stock, with the latest share price at $9.95, a 30 day share price return down 9.95% and a 1 year total shareholder return down 59.31%. This suggests momentum has been fading despite a slightly positive 90 day share price return of 2.37%.
If this kind of index reshuffle has you thinking about where else capital might be moving, it could be a useful moment to scan 20 top founder-led companies
With Perrigo trading at $9.95, showing steeply negative multi year returns and sitting at a sizeable discount to analyst price targets and some intrinsic value estimates, is there real undervaluation here, or is the market already pricing in future growth?
Most Popular Narrative: 39.7% Undervalued
Perrigo’s most followed narrative pegs fair value at $16.50 per share versus the recent $9.95 close, so the market discount hinges heavily on how its future earnings story plays out.
The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty.
Want to see what underpins that $16.50 fair value for Perrigo? The core thesis rests on modest revenue expectations, sharper margins, and a future earnings multiple that assumes real delivery. Curious which specific profit and valuation assumptions have to line up to support that upside gap?
Result: Fair Value of $16.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Perrigo’s narrative still runs into real pressure points, including ongoing softness in key OTC categories and intense infant nutrition competition that could limit revenue and margin progress.
Find out about the key risks to this Perrigo narrative.
Next Steps
With all this mixed sentiment around Perrigo, are you ready to move quickly and test the numbers against your own expectations using the 4 key rewards and 1 important warning sign?
Looking for more ideas beyond Perrigo?
If Perrigo’s story has you thinking about what else might deserve a spot on your watchlist, do not stop here. The next opportunity you research could be the one that truly reshapes your portfolio.
- Chase potential upside in smaller, higher risk opportunities by scanning 21 elite penny stocks with strong financials before the crowd catches on.
- Target quality at a discount by reviewing 44 high quality undervalued stocks that combine solid fundamentals with prices below many investors’ radar.
- Strengthen your portfolio’s resilience by filtering for 71 resilient stocks with low risk scores that may help balance out more volatile positions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com